A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

NCT01280721 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Interventions

DRUG: tolvaptan

Sponsor

Otsuka Pharmaceutical Co., Ltd.